Skip to main content
Premium Trial:

Request an Annual Quote

Affy's Answer to Next-Gen Sequencing: On-Chip 'Enzymatic Sequencing Reactions'

NEW YORK (GenomeWeb News) - Affymetrix said today that it is working on a new technology that combines DNA sequencing and microarrays.
 
Speaking at the JPMorgan Healthcare Conference in San Francisco today, Stephen Fodor, Affy's chairman and CEO, said the company will deploy enzymatic sequencing reactions directly on arrays that have captured portions of the genome, using new chemistry that "allows us to use both polymerase and ligase labeling reactions."
 
During the presentation, which was webcast, Fodor said the new technology is "one of the reasons why we acquired USB" - the reagent firm that Affymetrix purchased last month for $75 million.
 
USB, based in Cleveland, Ohio, sells molecular biology and biochemical reagent products. In 1980, the company commercialized Sequenase DNA polymerase and DNA sequencing kits.
 
Fodor did not provide further details on the sequencing chemistry used for the new system, or when Affy plans to make a sequencing product or service available.
 
He said in a Q&A session following the presentation that the "enzymatic sequence data" the technology will provide will be applied to new array products in the future.
 
Fodor also mentioned that Affy plans to launch a set of ultra-high-resolution copy number variation CHIPS during the first half of this year. Each of the three chips in the set will have 10 million 50-mer probes across the non-redundant part of the human genome, covering 1.5 billion bases in total.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.